Table 6.
Mean differences for the secondary outcome measures within groups, confidence intervals (CI), and effect sizes (ES) for the completers.
| Secondary outcome measuresa | Mean difference T2–T3b (n) |
95% CI T2–T3b |
Mean difference T2–T4c (n) |
95% CI T2–T4c |
ES T2–T3a |
P valued | ES T2–T4c |
P valued | |
| CPAQ |
|
|
|
|
|
|
|
|
|
|
|
Intervention | 8.75 (40) | 5.96-11.54 | 7.29 (34) | 3.11-11.47 | 0.58 | < .001 | 0.45 | .001 |
|
|
Control | 0.69 (36) | –2.90 to 4.29 | 0.40 (35) | –3.43 to 4.23 | 0.06 | .70 | 0.03 | .83 |
| FIQ |
|
|
|
|
|
|
|
|
|
|
|
Intervention | 3.10 (46) | –1.01 to 7.20 | 1.60 (36) | –4.40 to 7.60 | –0.17 | .14 | –0.09 | .59 |
|
|
Control | 6.61 (38) | 2.14-11.09 | 10.46 (39) | 6.43-14.49 | –0.36 | .005 | –0.62 | < .001 |
| SF-8, physical |
|
|
|
|
|
|
|
|
|
|
|
Intervention | –1.69 (39) | –3.96 to 0.59 | 0.06 (30) | –3.73 to 3.86 | –0.19 | .14 | 0.01 | .97 |
|
|
Control | –1.17 (29) | –4.18 to 1.83 | –2.41 (32) | –5.17 to 0.36 | –0.14 | .43 | –0.29 | .09 |
| SF-8, mental |
|
|
|
|
|
|
|
|
|
|
|
Intervention | 1.28 (39) | –1.72 to 4.28 | –1.51 (30) | –4.93 to 1.92 | 0.15 | .39 | –0.17 | .38 |
|
|
Control | –3.59 (29) | –7.04 to –0.14 | –4.92 (32) | –9.55 to –0.30 | –0.37 | 0.04 | –0.50 | .04 |
| GHQ-12 |
|
|
|
|
|
|
|
|
|
|
|
Intervention | 0.58 (43) | –0.06 to 1.22 | 0.80 (35) | –0.42 to 2.02 | –0.25 | .07 | –0.34 | .19 |
|
|
Control | 1.26 (34) | 0.59-1.94 | 2.38 (37) | 1.12-3.63 | –0.80 | .001 | –1.09 | < .001 |
| CPVI |
|
|
|
|
|
|
|
|
|
|
|
Intervention | 0.49 (44) | 0.26-0.72 | 0.15 (36) | –0.11 to 0.42 | 0.52 | < .001 | 0.16 | .25 |
|
|
Control | –0.22 (33) | –0.49 to 0.06 | –0.47 (34) | –0.83 to –0.10 | –0.28 | 0.12 | –0.63 | .01 |
| Pain, VAS |
|
|
|
|
|
|
|
|
|
|
|
Intervention | 1.11 (46) | –3.94 to 6.16 | 0.61 (36) | –7.03 to 8.24 | –0.05 | .66 | –0.03 | .87 |
|
|
Control | –0.99 (38) | –7.48 to 5.50 | 5.82 (38) | –1.26 to 12.90 | 0.04 | .76 | –0.26 | .10 |
| Fatigue, VAS |
|
|
|
|
|
|
|
|
|
|
|
Intervention | 1.13 (46) | –4.94 to 7.21 | 7.73 (36) | –2.26 to 17.72 | –0.04 | .71 | –0.29 | .13 |
|
|
Control | 5.44 (38) | –1.13 to 12.01 | 12.15 (38) | 6.29-18.00 | –0.22 | .10 | –0.51 | < .001 |
| Sleep disturbance, VAS |
|
|
|
|
|
|
|
|
|
|
|
Intervention | –0.14 (46) | –7.03 to 6.76 | 2.15 (36) | –7.81-12.12 | 0.01 | .97 | –0.08 | .66 |
|
|
Control | 3.96 (39) | –5.42 to 13.33 | 7.66 (39) | –0.62 to 15.95 | –0.15 | .40 | –0.30 | .07 |
a CPAQ: Chronic Pain Acceptance Questionnaire; FIQ: Fibromyalgia Impact Questionnaire; SF-8: Short-Form Health Survey; GHQ-12: General Health Questionnaire; CPVI: Chronic Pain Values Inventory; and VAS: visual analog scale.
b T2: at discharge; T3: immediately after intervention.
c T2: at discharge; T4: 5 months after intervention.
d P values for paired samples t tests.